Emrusolmin
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 2, 2024 (NCT06568237)
Timeline
Indications
Mechanism of action
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Brc1cccc(-c2cc(-c3ccc4c(c3)OCO4)n[nH]2)c1- Mol. weight
- 343.18 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4748063 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07197866 | Phase 2 | Sep 30, 2025 | Teva |
| NCT06911567 | Phase 1 | Mar 10, 2025 | Teva |
| NCT06627231 | Phase 1 | Oct 8, 2024 | Teva |
| NCT06568237 | Phase 2 | Oct 2, 2024 | Teva |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 4 | 4 | 2 | 2024 |
1 organizations
Page 1 / 1